BioNexus Gene Lab (BGLC) Fundamental Analysis: Revenue, Earnings & Valuation

7.06 / 10

Outperform

Fundamental analysis rates BGLC as Outperform with a 7.1/10 quality score. Profit‑to‑Market‑Value and Net‑Income‑to‑Revenue are strong, interest coverage is robust, but cash reserves and operating cash‑flow growth are weak. Overall, fundamentals support a constructive investment view.

Analysis Checks(3/10)

Revenue-MV

Value-0.11

Score0/3

Weight1.01%

1M Return0.22%

Net cash flow from operating activities per share (YoY growth rate %)

Value-1110.70

Score0/3

Weight-1.64%

1M Return-0.35%

Profit-MV

Value0.40

Score3/3

Weight42.84%

1M Return6.99%

Net income-Revenue

Value-0.15

Score2/3

Weight18.54%

1M Return3.37%

PB-ROE

Value0.22

Score0/3

Weight0.11%

1M Return0.03%

Cash-UP

Value-0.01

Score1/3

Weight-1.11%

1M Return-0.24%

Long-term debt to working capital ratio (%)

Value0.03

Score0/3

Weight2.38%

1M Return0.49%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score3/3

Weight38.38%

1M Return6.47%

Equity multiplier (DuPont analysis %)

Value1.19

Score0/3

Weight-3.02%

1M Return-0.63%

Current ratio

Value8.30

Score0/3

Weight2.51%

1M Return0.52%

Is BGLC fundamentally strong?

BGLC scores 7.06/10 on fundamentals and holds a Discounted valuation at present. Backed by its -25.74% ROE, -24.27% net margin, -1.31 P/E ratio, 0.56 P/B ratio, and -135.95% earnings growth, these metrics solidify its Outperform investment rating.